Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 3Not yet recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Other solid neoplasm 4Thoracic 2Sarcoma 2Gynecologic 1Genitourinary 1

Conditions

Biliary Tract Neoplasms 2Piebaldism 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
envafolimab × Gastrointestinal × 90 days × Clear all
NCT07599995 2026-05-20

GENE

Sir Run Run Shaw Hospital

Phase 2 Not yet recruiting
34 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07559864 2026-04-30

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
100 enrolled
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

NCT03667170 2026-03-25

KN035 for dMMR/MSI-H Advanced Solid Tumors

3D Medicines

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04910386 2026-03-25

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

3D Medicines

Phase 2 Not yet recruiting
126 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡